RxDoctor Payments Data

Emily Rountree, MD

Psychiatry · Mt Pleasant, SCNPI 1477635605

Payments from drug & device makers

$5,774in general payments, 2019–2025

Across 285 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$812
  • Neurocrine Biosciences, Inc.$680
  • Otsuka America Pharmaceutical, Inc.$642
  • Johnson & Johnson$622
  • Teva Pharmaceuticals USA, Inc.$545
  • AbbVie$495
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,773100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,774 in reported general payments places this provider in the 85th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,511
Medicare patients
45
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate24$228,136
Invega SustennaPaliperidone Palmitate55$139,372
AristadaAripiprazole Lauroxil15$48,241
UzedyRisperidone13$43,209
VraylarCariprazine Hcl18$42,272
Lurasidone Hcl12$8,669
Aripiprazole40$7,290
Paliperidone ErPaliperidone28$4,317
Haloperidol Decanoate41$2,228
Ziprasidone Hcl14$2,168
Divalproex Sodium52$1,837
Clozapine56$1,804
Olanzapine42$1,600
Fluphenazine Hcl20$1,329
Benztropine Mesylate75$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$622$367,50879 claims
Alkermes, Inc.Aristada$812$48,24115 claims
Teva Pharmaceuticals USA, Inc.Uzedy, Loxapine$545$44,11725 claims
AbbVieVraylar$495$42,27218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →